Prognostic benefit of GLP-1 RA addition to SGLT2i in patients with ASCVD and heart failure: a cohort study
Chen SY, Wu JY, Liao KM, Lin YM
Eur Heart J Cardiovasc Pharmacother. 2025:pvaf014.
Leggi
Breaking news
Finerenone and outpatient worsening heart failure with mildly reduced or preserved ejection fraction: a secondary analysis of the FINEARTS-HF randomized clinical trial
Cunningham JW, Chatur S, Claggett BL, et al.
JAMA Cardiol. 2025:e250016.
Leggi
The effect of empagliflozin on non-alcoholic fatty liver disease-related parameters in patients with type 2 diabetes mellitus: a randomized controlled trial
Shojaei F, Erfanifar A, Kalbasi S, et al.
BMC Endocr Disord. 2025;25(1):52.
Leggi
Glucagon-like peptide-1 receptor agonists and risk for depression in older adults with type 2 diabetes: a target trial emulation study
Tang H, Lu Y, Donahoo WT, et al.
Ann Intern Med. Pub. online 25 Feb 2025.
Leggi
Efficacy and safety of finerenone in type 2 diabetes: a pooled analysis of trials of heart failure and chronic kidney disease
Ostrominski JW, Claggett BL, Miao ZM, et al.
Diabetes Care. 2025:dc241873.
Leggi
Universal screening for hyperglycemia in early pregnancy and the risk of adverse pregnancy outcomes
Shen L, Zhang S, Wen J, et al.
BMC Pregnancy Childbirth. 2025;25(1):203.
Leggi
Association of normal range of urinary albumin-to-creatinine ratio with all-cause mortality among diabetic adults with preserved kidney function: National Health and Nutrition Examination Survey (NHANES) 2003-2018
Pang X, Dan W, Lin L
Diabetes Obes Metab. Pub. online 25 Feb 2025.
Leggi
The challenge of assessing impaired awareness of hypoglycaemia in diabetes in the era of continuous glucose monitoring: A narrative review of evidence and translation into clinical practice
Berry SA, Liarakos AL, Koutroukas V, et al.
Diabetes Obes Metab. Pub. online 25 Feb 2025.
Leggi
Time in range-A new gold standard in type 2 diabetes research?
Goshrani A, Lin R, O’Neal D, Ekinci EI
Diabetes Obes Metab. Pub. online 25 Feb 2025.
Leggi
Most hospitalised patients with type 2 diabetes benefit from continuous glucose monitoring compared to point-of-care glucose testing in a non-intensive care unit setting: a heterogeneity of treatment effect analysis
Olsen MT, Jensen SH, Rasmussen LM, et al.
Diabetes Obes Metab. Pub. online 25 Feb 2025.
Leggi